Evidence map›Paper›PMID 39527279›Full record

ArticleRheumatology international2024

A comparison of comorbidities and their risk factors prevalence across rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis with focus on cardiovascular diseases: data from a single center real-world cohort.

Zofia Guła, Katarzyna Łosińska, Piotr Kuszmiersz, Magdalena Strach, Jarosław Nowakowski, Grzegorz Biedroń, Olena Zimba, Łukasz Dyczek, Glenn Haugeberg, Mariusz Korkosz

Abstract readComparative Study
In one paragraph

Article in Rheumatology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Review
  5. Article
  6. Article
  7. Year in Review: Axial Spondyloarthritis.Mediterranean journal of rheumatology · 2026
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zofia GułaDepartment of Rheumatology, Immunology and Internal Medicine, University Hospital in Krakow, Krakow, Poland. zofia.gula@uj.edu.pl.ORCID 0000-0002-8698-6469
Katarzyna ŁosińskaDepartment of Rheumatology, Immunology and Internal Medicine, University Hospital in Krakow, Krakow, Poland.ORCID 0000-0003-2801-6584
Piotr KuszmierszDepartment of Rheumatology, Immunology and Internal Medicine, University Hospital in Krakow, Krakow, Poland.ORCID 0000-0002-2031-6657
Magdalena StrachDepartment of Rheumatology, Immunology and Internal Medicine, University Hospital in Krakow, Krakow, Poland.ORCID 0000-0001-5449-0680
Jarosław NowakowskiDepartment of Rheumatology, Immunology and Internal Medicine, University Hospital in Krakow, Krakow, Poland.ORCID 0000-0002-8748-7581
Grzegorz BiedrońDepartment of Rheumatology, Immunology and Internal Medicine, University Hospital in Krakow, Krakow, Poland.ORCID 0000-0002-2643-9818
Olena ZimbaDepartment of Rheumatology, Immunology and Internal Medicine, University Hospital in Krakow, Krakow, Poland.ORCID 0000-0002-4188-8486
Łukasz DyczekDepartment of Rheumatology, Immunology and Internal Medicine, University Hospital in Krakow, Krakow, Poland.ORCID 0009-0001-9650-9973
Glenn HaugebergDivision of Rheumatology, Department of Internal Medicine, Sørlandet Hospital, Kristiansand, Norway.ORCID 0000-0002-9279-5191
Mariusz KorkoszDepartment of Rheumatology, Immunology and Internal Medicine, University Hospital in Krakow, Krakow, Poland.ORCID 0000-0002-1749-9739

Funding

POLNOR-RHEUMA 0026/2019-00
6 · The paper itself

Abstract

Management of comorbidities is essential to a patient-centered approach to the treatment of chronic inflammatory arthritis. The aim of this study was to compare the prevalence of comorbidities and their risk factors in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) in a single center outpatient cohort. This cross-sectional study included adult patients diagnosed with RA, PsA, and axSpA from a single rheumatology outpatient center. Comorbidities were documented by physicians, and patients were categorized into two age groups, younger (< 45 years) and older (≥ 45 years), with age- and gender-based comparisons. Disease activity, comorbidities, and cardiovascular (CV) risk factors were analyzed using chi-squared tests for categorical variables and independent samples t-tests for continuous variables, with p values < 0.05 considered statistically significant. Comorbidities were registered by physicians using GoTreatIt® Rheuma software. Among 508 RA, 267 PsA, and 285 axSpA patients, the four most common comorbidities were hypertension (36.4%, 25.1%, and 19.7%, respectively), dyslipidemia (19.5%, 15.4%, 14.7% respectively), obesity (16.9%, 22.5%, 14% respectively) and thyroid disease (21.5%, 13.9%, 11.2% respectively). Other comorbidities differed among the diseases and included osteoporosis, osteoarthritis, diabetes mellitus, arrhythmia, and asthma in RA, diabetes mellitus, depression and asthma in PsA, osteoporosis and serious infection in axSpA. RA patients, compared to axSpA had a higher prevalence of coronary artery disease (4.1% vs. 0.7%, p = 0.006), arrhythmia (6.9% vs. 2.5%, p = 0.008) and major adverse cardiac events (2.6% vs. 0.4%, p = 0.024) compared to axSpA. Osteoporosis was more frequent in RA (19.1%) and axSpA (8.4%) than in PsA (2.3%; p < 0.001) and was frequently diagnosed in patients aged < 45. Depression prevalence was surprisingly low (1.6%, 5.2%, and 1.8%, respectively). RA patients had the highest multimorbidity rate, with 26.6% reporting three or more comorbidities, compared to 16.8% in PsA and 10.6% in axSpA (p < 0.001). Health status was poorest in RA and worse in women compared to men for all diseases. RA, PsA, and axSpA share the same four most common comorbidities: hypertension, dyslipidemia, obesity, and thyroid disease but have different prevalence of other disorders and CV risk factors, indicating the need for an individual screening and prevention approach. The possible unrecognition of depression should be evaluated.

Indexed as

Arthritis, PsoriaticArthritis, RheumatoidCardiovascular DiseasesComorbidityAdultAgedAxial SpondyloarthritisCross-Sectional StudiesDyslipidemiasFemaleHumansHypertensionMaleMiddle AgedPrevalenceRisk FactorsAxial spondyloarthritisCardiovascular diseasesCardiovascular riskComorbiditiesDepressionDyslipidemiaHypertensionInflammatory arthritisObesityOsteoporosisPsoriatic arthritisReal-world data.comorbiditiesReal-world evidenceRheumatoid arthritisRisk factors

Identifiers

PMID39527279
PMCPMC11618134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.